A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：2

作者：

Topp, Max S. ^{[1
]}

Duell, Johannes ^{[1
]}

Li, Jingjin ^{[2
]}

Jankovic, Vladimir ^{[2
]}

Lowy, Israel ^{[2
]}

Sternberg, David ^{[2
]}

Adriaens, Lieve ^{[2
]}

Peterman, Mary ^{[2
]}

Ambati, Srikanth R. ^{[2
]}

Bannerji, Rajat ^{[3
]}

机构：

[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126670

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4007

引用

页数：4

共 50 条

[31] Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
Villasboas, Jose Caetano
Kline, Justin Paul
Lazaryan, Aleksandr
Bartlett, Nancy L.
Hernandez-Ilizaliturri, Francisco J.
Awan, Farrukh Tauseef
Geethakumari, Praveen Ramakrishnan
Karmali, Reem
Shune, Leyla
Lansigan, Frederick
Reeder, Craig B.
Diefenbach, Catherine S. Magid
Sharon, Elad
Atherton, Pamela J.
Fiskum, Jack
Yin, Jun
Adjei, Alex A.
Ansell, Stephen M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[32] BISPECIFIC ANTIIDIOTYPE ANTI-CD3 ANTIBODY THERAPY OF MURINE B-CELL LYMPHOMA
WEINER, GJ
HILLSTROM, JR
JOURNAL OF IMMUNOLOGY, 1991, 147 (11): : 4035 - 4044
[33] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
Lu, Chia-Yen
Chen, Gregory J.
Tai, Pei-Han
Yang, Yu-Chen
Hsu, Yu-Shen
Chang, Mingi
Hsu, Chuan-Lung
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
[34] PHASE I CLINICAL TRIAL TARGETING CD20+NON-HODGKIN'S LYMPHOMA (NHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT WITH ANTI-CD3 x ANTI-CD20 BISPECIFIC ANTIBODY ARMED T CELLS
Lum, L. G.
Thakur, A.
Ratanatharathorn, V
Al-Kadhimi, Z.
Paul, E.
Skuba, C.
Steel, P.
Ayash, L.
Abidi, M.
Wedge, J.
Uberti, J. P.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S158 - S159
[35] A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Yan, Zixun
Sheng, Lingshuang
Wang, Li
Wu, Wen
Zhang, Yilun
Shen, Rong
Cao, Weiguo
Li, Lei
Chen, Sheng
Jiang, Xufeng
Yi, Hongmei
Song, Qi
Wang, Li
Cheng, Shu
Xu, Peng-Peng
Li, Jianyong
Zhao, Weili
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Anti-CD20 therapy for older patients with B-cell non-Hodgkin lymphoma in the context of epidemic normalization
Zhang, Dongdong
Xu, Shuangnian
ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3290 - 3292
[37] b Relapsed and refractory malignant B cell diseases: Evidence for therapeutic efficacy via subcutaneous administration of anti-CD20 x anti-CD3 antibody lymphomun
Buhmann, R.
Ruf, P.
Hess, J.
Lindhofer, H.
Jacob, U.
Dreyling, M.
BONE MARROW TRANSPLANTATION, 2017, 52 : S505 - S505
[38] Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+B-cell non-Hodgkin lymphoma (B-NHL).
Sangha, Randeep S.
Davies, Andrew John
Dang, Nam H.
Ogura, Michinori
Paccagnella, M. Luisa
Ananthakrishnan, Revathi
Vandendries, Erik
Tee, Goh Yeow
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[39] First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.
Brownstein, Carrie M.
Adriaens, Lieve
Bannerji, Rajat
Chavez, Julio C.
Levy, Ronald
Ansell, Stephen Maxted
Advani, Ranjana H.
Patel, Snehal
Kostic, Ana
Trail, Pamela
Lowy, Israel
Kohrt, Holbrook Edwin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Larson, Sarah M.
Chen, Yvonne Y.
Johnston, Jim
Roy, Sylvain
Patel, Pinakin
Benjamin, Jonathan E.
BLOOD, 2023, 142

← 1 2 3 4 5 →